Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
REDWOOD CITY, Calif., Nov. 10, 2016 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at the 7th Annual Craig-Hallum Alpha Select Conference on Wednesday, November 16, at 11:20 a.m. Eastern time (8:20 a.m. Pacific time). The conference is being held at the Sheraton Times Square Hotel in New York City.
A live webcast and replay of the presentation will be available on the Investors section of the company's website, http://ir.codexis.com/.
About Codexis, Inc.
Codexis, Inc. is a leading developer of biocatalysts for pharmaceutical and fine chemical production. The company’s patent portfolio includes more than 850 patents and patent applications worldwide that cover its novel enzymes and proprietary methods for engineering new enzymes and their applications. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Contacts:
Investors
LHA
Jody Cain, 310 691 7100
[email protected]
Media
That’s Nice LLC
Guy Tiene
[email protected]
